Literature DB >> 23184055

Loss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency.

Marieta M Ruseva1, Katherine A Vernon, Allison M Lesher, Wilhelm J Schwaeble, Youssif M Ali, Marina Botto, Terence Cook, Wenchao Song, Cordula M Stover, Matthew Caleb Pickering.   

Abstract

Complement factor H (CFH) is a negative regulator of the alternative pathway of complement, and properdin is the sole positive regulator. CFH-deficient mice (CFH(-/-)) develop uncontrolled C3 activation and spontaneous renal disease characterized by accumulation of C3 along the glomerular basement membrane, but the role of properdin in the pathophysiology is unknown. Here, we studied mice deficient in both CFH and properdin (CFH(-/-).P(-/-)). Although CFH(-/-) mice had plasma depleted of both C3 and C5, CFH(-/-).P(-/-) animals exhibited depletion of C3 predominantly, recapitulating the plasma complement profile observed in humans with properdin-independent C3 nephritic factors. Glomerular inflammation, thickening of the capillary wall, and glomerular C3 staining were significantly increased in CFH(-/-).P(-/-) compared with CFH(-/-) mice. We previously reported that exogenous CFH ameliorates C3 staining of the glomerular basement membrane and triggers the appearance of mesangial C3 deposits in CFH(-/-) mice; here, we show that these effects require properdin. In summary, during uncontrolled activation of C3 driven by complete CFH deficiency, properdin influences the intraglomerular localization of C3, suggesting that therapeutic inhibition of properdin would be detrimental in this setting.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23184055      PMCID: PMC3537217          DOI: 10.1681/ASN.2012060571

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   14.978


  29 in total

1.  Genetic and therapeutic targeting of properdin in mice prevents complement-mediated tissue injury.

Authors:  Yuko Kimura; Lin Zhou; Takashi Miwa; Wen-Chao Song
Journal:  J Clin Invest       Date:  2010-10       Impact factor: 14.808

2.  A properdin dependent nephritic factor slowly activating C3, C5, and C9 in membranoproliferative glomerulonephritis, types I and III.

Authors:  C W Clardy; J Forristal; C F Strife; C D West
Journal:  Clin Immunol Immunopathol       Date:  1989-03

Review 3.  Dense deposit disease.

Authors:  Richard J H Smith; Claire L Harris; Matthew C Pickering
Journal:  Mol Immunol       Date:  2011-05-24       Impact factor: 4.407

4.  Another Swedish family with complete properdin deficiency: association with fulminant meningococcal disease in one male family member.

Authors:  C Söderström; A G Sjöholm; R Svensson; S Ostenson
Journal:  Scand J Infect Dis       Date:  1989

5.  Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF.

Authors:  Y Tanuma; H Ohi; M Hatano
Journal:  Clin Immunol Immunopathol       Date:  1990-08

Review 6.  Properdin: emerging roles of a pattern-recognition molecule.

Authors:  Claudia Kemper; John P Atkinson; Dennis E Hourcade
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

7.  Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H.

Authors:  Matthew C Pickering; H Terence Cook; Joanna Warren; Anne E Bygrave; Jill Moss; Mark J Walport; Marina Botto
Journal:  Nat Genet       Date:  2002-07-01       Impact factor: 38.330

Review 8.  Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals.

Authors:  M C Pickering; H T Cook
Journal:  Clin Exp Immunol       Date:  2008-02       Impact factor: 4.330

9.  Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency.

Authors:  K Høgåsen; J H Jansen; T E Mollnes; J Hovdenes; M Harboe
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

Review 10.  Regulating complement in the kidney: insights from CFHR5 nephropathy.

Authors:  Daniel P Gale; Matthew C Pickering
Journal:  Dis Model Mech       Date:  2011-11       Impact factor: 5.758

View more
  33 in total

1.  Blocking Properdin Prevents Complement-Mediated Hemolytic Uremic Syndrome and Systemic Thrombophilia.

Authors:  Yoshiyasu Ueda; Takashi Miwa; Damodar Gullipalli; Sayaka Sato; Daisuke Ito; Hangsoo Kim; Matthew Palmer; Wen-Chao Song
Journal:  J Am Soc Nephrol       Date:  2018-06-01       Impact factor: 10.121

2.  Efficacy of Targeted Complement Inhibition in Experimental C3 Glomerulopathy.

Authors:  Marieta M Ruseva; Tao Peng; Melissa A Lasaro; Keith Bouchard; Susan Liu-Chen; Fang Sun; Zhao-Xue Yu; Andre Marozsan; Yi Wang; Matthew C Pickering
Journal:  J Am Soc Nephrol       Date:  2015-06-05       Impact factor: 10.121

3.  Targeting properdin in the treatment of atypical haemolytic uraemic syndrome: better than eculizumab?

Authors:  Kate Smith-Jackson; Kevin J Marchbank
Journal:  Ann Transl Med       Date:  2018-11

4.  Complement Factor H-Related 5-Hybrid Proteins Anchor Properdin and Activate Complement at Self-Surfaces.

Authors:  Qian Chen; Melanie Manzke; Andrea Hartmann; Maike Büttner; Kerstin Amann; Diana Pauly; Michael Wiesener; Christine Skerka; Peter F Zipfel
Journal:  J Am Soc Nephrol       Date:  2015-10-02       Impact factor: 10.121

5.  C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy.

Authors:  Allison Lesher Williams; Damodar Gullipalli; Yoshiyasu Ueda; Sayaka Sato; Lin Zhou; Takashi Miwa; Kenneth S Tung; Wen-Chao Song
Journal:  Kidney Int       Date:  2017-01-27       Impact factor: 10.612

Review 6.  Therapeutic control of complement activation at the level of the central component C3.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Immunobiology       Date:  2015-06-10       Impact factor: 3.144

7.  Partial Complement Factor H Deficiency Associates with C3 Glomerulopathy and Thrombotic Microangiopathy.

Authors:  Katherine A Vernon; Marieta M Ruseva; H Terence Cook; Marina Botto; Talat H Malik; Matthew C Pickering
Journal:  J Am Soc Nephrol       Date:  2015-09-15       Impact factor: 10.121

Review 8.  C3 glomerulopathy - understanding a rare complement-driven renal disease.

Authors:  Richard J H Smith; Gerald B Appel; Anna M Blom; H Terence Cook; Vivette D D'Agati; Fadi Fakhouri; Véronique Fremeaux-Bacchi; Mihály Józsi; David Kavanagh; John D Lambris; Marina Noris; Matthew C Pickering; Giuseppe Remuzzi; Santiago Rodriguez de Córdoba; Sanjeev Sethi; Johan Van der Vlag; Peter F Zipfel; Carla M Nester
Journal:  Nat Rev Nephrol       Date:  2019-03       Impact factor: 28.314

9.  Blocking properdin, the alternative pathway, and anaphylatoxin receptors ameliorates renal ischemia-reperfusion injury in decay-accelerating factor and CD59 double-knockout mice.

Authors:  Takashi Miwa; Sayaka Sato; Damodar Gullipalli; Masaomi Nangaku; Wen-Chao Song
Journal:  J Immunol       Date:  2013-02-20       Impact factor: 5.422

10.  Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis.

Authors:  Allison M Lesher; Lin Zhou; Yuko Kimura; Sayaka Sato; Damodar Gullipalli; Andrew P Herbert; Paul N Barlow; Hannes U Eberhardt; Christina Skerka; Peter F Zipfel; Takayuki Hamano; Takashi Miwa; Kenneth S Tung; Wen-Chao Song
Journal:  J Am Soc Nephrol       Date:  2012-11-30       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.